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The incidence of larynx cancer in the United States is around 4.5 cases per 100,000
per year (1) . The 5-year relative survival percentage for localized disease has been stable at around 70-80% for the last 20 years(1). In early laryngeal cancer, radiotherapy is an effective treatment modality, with local control rates between 80-90% for T1 tumors (2) . Partial laryngectomy or CO2 laser resection are alternative treatments with comparable survival rates, although when used as salvage after a failed radiotherapy course they have a higher complication rate (3) . Treatment choice is mainly based on the estimated functional outcome and the preferences of the clinician. It would therefore be useful to predict beforehand which patients will benefit from radiotherapy. Prediction of resistance is also likely to be increasingly useful in the development of biological modifiers which increase the effects of radiation, providing an alternative treatment for resistant tumors.
Important clinical factors associated with local recurrence after radiotherapy are tumor stage, tumor size, radiotherapy fraction size and year of treatment (4) . Treatment choice is now mainly based on T-stage,(5) although this is still a relatively poor indicator of survival (6) Since clinical factors cannot provide an accurate prediction, it is likely that recurrence of a tumor can partly be explained by tumor biology. Three biological processes known to influence response to radiotherapy are intrinsic radiosensitivity (7), hypoxia (8) and repopulation (9). For each of these processes, individual markers (mainly immunohistochemical) have been investigated and found to be of predictive value (10-12), although none have been sufficiently validated or are in routine use. Since many genes are involved in each process, in addition to single markers representing these processes, sets of markers (gene sets) for hypoxia (13;14) , intrinsic radiosensitivity (15) (16) (17) and repopulation (18) have also been defined. Another factor more recently hypothesized to play a role in response to therapy is the number of stem To date, no studies have investigated all these processes simultaneously.
Microarrays have been used to measure gene expression (mRNA) on a genome wide scale, and can in principle monitor all the above-mentioned processes concurrently.
However, only one microarray study with 14 patients has been carried out for patients treated with radiotherapy alone (21) . Several expression profiling studies have been carried out on patients treated with radiotherapy in combination with surgery or chemotherapy (22) (23) (24) (25) (26) . However, these have often included heterogeneous groups of patients and cannot address the question of factors affecting the response of laryngeal cancer to radiation alone.
Our objective was to find a gene expression profile that will accurately predict local recurrence after radiotherapy in a homogeneous group of patients with early laryngeal carcinoma. We chose to study early stage tumors, since these are likely to be more homogeneous than advanced tumors and also technically easier to treat, minimizing the chance of geographical misses. Treatment failure is then highly likely to be due to biological rather than technical factors. In addition to giving more insight into the molecular processes underlying treatment failure, accurate prediction would enable treatment to be individualized, leading to increased survival and less unnecessary morbidity. We studied two series of early stage larynx cancer patients treated with radiotherapy alone. The first was a test series of frozen tumor specimens used to study global gene expression to discover predictive markers for local control, which were then validated on a second series by immunohistochemistry.
MATERIALS AND METHODS

Gene expression series
Patients. Fifty two patients were recruited from five different institutes in The Netherlands and were eligible if they had been treated for a T1 or T2 larynx carcinoma (see supplemental table 1) , and pre-treatment fresh frozen tumor material was available.
Patients were treated between 1997 and 2005, and staging was done either clinically or with a CT-scan. Because patients with small tumors did not have a CT-scan, tumor volumes could not be measured for the whole group. Treatment was radiotherapy alone with curative intent, applying fractionation schemes standard in each of the five centers.
To compare different radiotherapy schedules, the equivalent dose in 2-Gy fractions (EQD 2 ) was calculated for every patient with the formula:
where D is the total dose, d the given fraction dose, the α/β ratio was assumed to be 10.
Recurrence was defined as a histologically proven local tumor recurrence within two years of the initial treatment, to ensure the analysis of true recurrences rather than second primaries. Since we planned to study a matched series, for every patient with a recurrence we aimed to include two controls, with a recurrence-free follow-up of at least two years and matched for the institute they were treated in, T-stage, subsite, gender and age. There were no significant differences between groups with and without local where at least 20% of samples had a minimum fold change greater than 1.35 and a pvalue for log-ratio variation under 0.01. The filtered set was entered in a nearest centroid model that finds genes that best predict local recurrence. Genes significantly different between the patients with and without recurrence at the p<0.01 significance level were used for class prediction. The leave-one-out cross-validation method was used to compute mis-classification rates.
Immunohistochemistry series
Patients. Of the patients included in the mRNA expression microarray series, paraffin embedded material for immunohistochemistry (IHC) was used from two of the five institutes (Amsterdam and Groningen). This small subset of 20 cases was used to confirm gene expression values by IHC. A second matched series of 76 patients was used as an independent validation series of our findings from the gene expression study.
Paraffin embedded biopsies were used to make cores for a tissue microarray (TMA). The construction of the TMA and the patient characteristics were described previously (10). Briefly, the patients were predominantly male with stage T1 and T2 glottic tumors given a median of 66Gy in 2Gy fractions (supplemental table 2).
Immunohistochemistry staining.
Sections of 3μm were cut from either whole tissue blocks or the TMA and mounted on amino-propyl-ethoxy-silan (APES, Sigma-Aldrich, Diesenhofen Germany)-coated glass slides. Slides were deparaffinized in xylene and rehydrated in ethanol. Antigen retrieval comprised boiling the slides in a microwave oven in citrate (pH 6.0) for 15 minutes.
Endogenous peroxidase was blocked with 0.3% hydrogen peroxidase for 30 minutes.
Slides were incubated with a mouse monoclonal antibodies against CD44 (156-3C11; were generated using the same methods and materials as described above for the tumor biopsies.
RESULTS
Gene expression
Gene expression analysis. Exclusion of probes that did not exceed background expression in any patient left 26,454 probes for analysis. Gene expression signatures for hypoxia, intrinsic radiosensitivity, repopulation and stem cells were analyzed in a logistic regression (table 1) . The putative stem cell marker CD44 was the most significant, with an unrelated stem cell signature as second most significant. A third stem cell signature not including CD44 (see supplemental figure 1A ). When patients were divided into three groups of low, medium and high CD44 expression, split so that there were equal numbers of recurrences in each group, the odds of recurrence (number of recurrences divided by number of non-recurrences for each group) was 15.2 fold higher in the highest CD44 expression group compared with the lowest (p=0.003, figure 1B ).
Expression of acute hypoxia genes was also associated with local recurrence, although significance was lost after correction for multiple testing. Radiosensitivity and proliferation genes showed no relationship with recurrence.
After restriction of the dataset to those 8,317 probes that showed significant differences in expression between the tumors, thus removing uninformative probes, we performed a data-driven analysis for which genes best predicted recurrence. When the univariate significance alpha level was set to p<0.01, 34 probes (18 up and 16 downregulated in tumors subsequently recurring) were found to be predictive (table 2) . The most significant upregulated marker discriminating between cures and recurrences was CD44 (p< 0.002). With the nearest centroid method only 23% of the patients were correctly classified with these 34 genes. In addition, false discovery rates, as calculated by the Benjamini-Hochberg method, were high. However, despite the predictive weakness of the signature as a whole, of note was that all three probes for CD44 that were present on the array appeared in the top 10 highest ranking upregulated genes. figure 3A ). As before, when patients were divided into three groups with low, medium and high CD44 expression, split to ensure equal numbers of recurrences per group, the odds ratio for recurrence was 6.1 fold higher in the highest group compared with the lowest (p=0.005, figure 3B ). These data on protein expression thus confirm the mRNA expression data.
Larynx cancer cell lines
In addition to cellular radiosensitivity, the effectiveness of fractionated radiotherapy can be determined by microenvironmental factors such as hypoxia, repopulation rates during therapy, and the fraction of stem cells. As a first step in attempting to dissect the role played by CD44 on these factors, we studied a series of larynx cancer cell lines under well controlled in vitro conditions. As shown in figure 4 , CD44 mRNA levels (average for the three probes) correlated significantly with plating efficiency (p = 0.03). Since plating efficiency has been correlated with tumor initiating capacity in several studies, this is consistent with CD44 being a stem cell marker in this tumor type. In the same experiments, CD44 expression did not correlate with intrinsic radiosensitivity in these 9 larynx cancer cell lines (p-value = 0.71). None of the three CD44 probes individually showed a correlation with radiosensitivity, while two out of three CD44 probes show a significant correlation with plating efficiency (supplemental table 4). These data imply that CD44 expression is not monitoring intrinsic radiosensitivity but rather the fraction of stem cells. The aim of this study was to find prediction markers for clinical outcome of larynx cancer after radiotherapy using gene expression profiling. We chose to study early stage tumors since these will be inherently less variable than advanced cancer both in terms of genetically different subpopulations and variability in blood flow and hypoxia. In addition, delivery of the radiotherapy is less complicated with less chance of geographical misses.
Any recurrences are therefore likely to be due to inherent resistance of the tumor cells.
Secondly, we chose to match recurrent and non-recurrent patients for the most important known clinical variables (T-stage, subsite, treatment, gender and age), so that these would not be confounding factors in the analysis.
In the test series, we studied the expression of several sets of genes monitoring biological processes known to influence the outcome of radiotherapy. We found that CD44, chosen as a stem cell marker, showed the most significant correlation with local recurrence. Expression of genes monitoring proliferation and intrinsic radiosensitivity showed no correlation with outcome. A gene set defining acute hypoxia showed a trend, although not significant when corrected for multiple testing. In a separate data-driven analysis including over 8000 genes (after filtering out genes not showing significant expression or significant variation across the samples), the three probes for CD44 came out high in the ranking list of genes correlating with recurrence, one of the probes being the most significant of all genes tested. This non-hypothesis-driven approach supported the hypothesis-driven approach, indicating that CD44 is a good predictor of outcome after radiotherapy in these head and neck squamous cell carcinomas. Furthermore, in an independent validation series, CD44 protein expression measured immunohistochemically correlated significantly with outcome, such that higher CD44
scores were associated with a higher chance of local recurrence. Since both these were matched series, results are independent of the most important clinical predictors. CD44v6 presence in these margins, detected with immunohistochemistry, was predictive of recurrence (36) . Wang et al (37) found that one CD44 isoform (v10) was associated with reduced disease free survival in HNSCC. These, together with the present study, support CD44 expression as a negative predictive factor.
We chose CD44 as a stem cell marker for HNSCC, since Prince et al. (31) showed that CD44 positive cells in this tumor type were up to an order of magnitude acts as co-receptor for the erbB family which can lead to activation of the PI3K/AKT pathway, a pathway known to promote survival after cytotoxic damage, including after irradiation. This suggests a possible link between CD44 expression and intrinsic radiosensitivity. However, we did not find a correlation between CD44 expression and radiosensitivity in the panel of larynx cancer cell lines. Alternatives therefore need to be sought to explain the relationship between CD44 expression and radiocurability.
Other possibilities are links with hypoxia or repopulating ability, both known to influence radiotherapy outcome. We found that CD44 expression correlated with expression of acute hypoxia genes (supplemental figure 4 ) and a trend (p=0.08) that expression of acute hypoxia genes correlated with chance of recurrence. No significant relationship with expression of chronic hypoxia genes was found. This is consistent with other studies indicating that cells hypoxic for relatively short times are more dangerous than those chronically exposed to hypoxia (40;41). We found no evidence of a link between CD44 expression and proliferation associated genes, or in this series between expression of proliferation genes and outcome. This is consistent with our earlier expression profiling studies on advanced head and neck tumors treated with radiotherapy and cisplatin, where proliferation genes were not predictive (25) . Whether this is due to relatively slow repopulation rates in these tumors, or because the signatures do not adequately monitor repopulation capacity during fractioned radiotherapy is not known. initiating fraction) will be directly correlated with the CD44-positive fraction. In the current study, this fraction varied by a factor of around 3. Based on Poisson statistics, such a three-fold change in the effective number of cells which need to be killed by radiation would lead to an absolute change in the cure probability of around 30%; e.g. 1 surviving cell on average would lead to 37% cure probability, whereas 3 surviving cells on average would lead to a 5% cure probability. It is therefore possible that the relationship between cure and CD44 expression is a reflection of the number of cancer initiating cells needed to be killed. This is independent of whether the putative stem cells are more or less radioresistant than bulk tumor cells. (42) (43) (44) . In addition, the Glinsky signature, a putative stem cell signature, also showed a strong trend with outcome in the test series (table 1) . This BMI-1-driven signature was derived by comparing primary and metastatic prostate cancer. We performed an Ingenuity pathway analysis on this 11-gene signature, also including CD44. The only significant pathway resulting from the analysis showed a link between the Glinsky genes and CD44 through an interaction with TGFB1 (supplementary figure 2) . While not definitive, these data support the notion that CD44 is in some way monitoring stem cell capacity. Table 1 . Logistic regression of gene sets with local recurrence. Range: lowest to highest value of either Pearson correlations against the weights of a gene set or, for gene sets without weights, the average expression (log2 scale) of the genes in the set. OR: odds ratios with corresponding confidence intervals and p-values were generated from a logistic regression of Pearson or average values of the gene sets with local recurrence data. In order to give comparable odds ratios, some Pearson correlations were multiplied by 5 or 10 (not changing the p-values). 
